Interim Results Announced of US Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% CRR, and Favorable Safety Profile 

“Today is a very important day for Alpha Tau. These results confirm that we are on target with pursuing our core strategy of offering new treatment possibilities to those who need it most,” commented Uzi Sofer, CEO of Alpha Tau. “Glioblastoma is one of the most devastating diagnoses in oncology. Approximately 14,000 Americans are newly diagnosed each year, recurrence is virtually inevitable, and the five-year survival rate remains below 10% – once the disease returns, median survival is typically measured in only a handful of months.  These results are extremely exciting and we look forward to continuing to treat patients in our recurrent glioblastoma trial, pending FDA confirmation following review of our safety report, and to expanding this work into further indications in brain cancer and other high-mortality settings where patients urgently need new approaches.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib